Advertisement
Australia markets close in 3 hours 25 minutes

  • ALL ORDS

    7,943.40
    +45.90 (+0.58%)
     

  • ASX 200

    7,673.60
    +44.60 (+0.58%)
     

  • AUD/USD

    0.6618
    +0.0006 (+0.09%)
     

  • OIL

    78.42
    +0.31 (+0.40%)
     

  • GOLD

    2,320.40
    +11.80 (+0.51%)
     

  • Bitcoin AUD

    96,859.42
    +1,164.75 (+1.22%)
     

  • CMC Crypto 200

    1,334.68
    +57.70 (+4.52%)
     

  • AUD/EUR

    0.6145
    +0.0005 (+0.08%)
     

  • AUD/NZD

    1.1019
    +0.0026 (+0.24%)
     

  • NZX 50

    11,835.27
    -102.81 (-0.86%)
     

  • NASDAQ

    17,890.79
    +349.29 (+1.99%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • Dow Jones

    38,675.68
    +449.98 (+1.18%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • Hang Seng

    18,435.52
    -40.40 (-0.22%)
     

  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     

Orion Corporation: Managers’ transactions – Virve Laitinen

Orion Oyj
·1-min read
Orion Oyj
Orion Oyj

ORION CORPORATION
MANAGERS’ TRANSACTIONS
4 MARCH 2024 at 13.00 EET

Orion Corporation: Managers’ transactions – Virve Laitinen

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Virve Laitinen
Position: Other senior manager
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 54274/5/4

ADVERTISEMENT

____________________________________________
Transaction date: 2024-03-01
Outside a trading venue
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE

Transaction details
(1): Volume: 7282 Unit price: 0 EUR

Aggregated transactions (1):
Volume: 7282 Volume weighted average price: 0 EUR

Orion Corporation

Liisa Hurme

President and CEO

   

Olli Huotari

SVP, Corporate Functions

 

                                                

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.